|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018802,
umls-concept:C0025598,
umls-concept:C0026565,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0038766,
umls-concept:C0071097,
umls-concept:C0289313,
umls-concept:C0332307,
umls-concept:C0936012,
umls-concept:C1514923,
umls-concept:C1956346
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-5-7
|
|
pubmed:abstractText |
Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients from our electronic health record (EHR). We observed no differences in CAD risk among the agents. Metformin was associated with a reduced risk of CHF (HR 0.76, 95% CI 0.64-0.91) and mortality (HR 0.54, 95% CI 0.46-0.64) when compared to sulfonylurea. Pioglitazone was also associated with a lower risk of mortality when compared to sulfonylurea (HR 0.59, 95% CI 0.43-0.81). No other significant differences were found between the oral agents. In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1432-5233
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
145-54
|
|
pubmed:meshHeading |
pubmed-meshheading:19194648-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:19194648-Coronary Artery Bypass,
pubmed-meshheading:19194648-Coronary Disease,
pubmed-meshheading:19194648-Diabetes Mellitus, Type 2,
pubmed-meshheading:19194648-Diabetic Angiopathies,
pubmed-meshheading:19194648-Female,
pubmed-meshheading:19194648-Heart Failure,
pubmed-meshheading:19194648-Humans,
pubmed-meshheading:19194648-Hypoglycemic Agents,
pubmed-meshheading:19194648-Male,
pubmed-meshheading:19194648-Metformin,
pubmed-meshheading:19194648-Multivariate Analysis,
pubmed-meshheading:19194648-Proportional Hazards Models,
pubmed-meshheading:19194648-Retrospective Studies,
pubmed-meshheading:19194648-Risk Factors,
pubmed-meshheading:19194648-Smoking,
pubmed-meshheading:19194648-Sulfonylurea Compounds,
pubmed-meshheading:19194648-Survival Analysis,
pubmed-meshheading:19194648-Survivors,
pubmed-meshheading:19194648-Thiazolidinediones
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
|
|
pubmed:affiliation |
Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue NA10, Cleveland, OH, 44195, USA. pantalk@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
